Patients at high risk for pulmonary complications had similar support needs at 90 days with HFNOT or standard oxygen.

Key points A 69-year-old man presented to a dermatology clinic with a 1-day history of a painful erythematous rash. Four days ...

A High Court judge has dismissed a clinical negligence claim brought by a young man who lost most of his sight following ...

A recent study published in CHEST found that treatment-naïve adults with obesity-hypoventilation syndrome receiving a combination of acetazolamide and atomoxetine for 2 weeks had improved ...

Nationally, there has been a rise in the number of children and adolescents with congenital and acquired heart disease ...

Almost 30,000 people in England with chronic obstructive pulmonary disease (COPD) could soon have access to a biologic treatment, Sanofi and Regeneron's Dupixent, after it was recommended for use by ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Shortness of breath can be triggered by different factors such as anxiety, stress, or intense workouts. The medical term for ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Rival treatments had mixed results in the past AstraZeneca sees $3-5 billion peak annual sales for its drug Detailed results to be presented at upcoming medical conference Shares among biggest gainers ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.